Prime Medicine (NASDAQ:PRME) reported full-year 2025 financial results on Tuesday, signaling a strategic shift toward commercial-stage readiness as its "search-and-replace" gene editing platform achieves its first human clinical validations.
The Cambridge, Massachusetts-based biotech reported a net loss of $201.1 million for the year ended December 31, 2025.
This loss reflects a heavy investment in its Prime Editing platform, with research and development (R&D) expenses totaling $160.6 million.
General and administrative (G&A) costs were reported at $52.3 million.
The company ended the year with $191.4 million in cash, cash equivalents, and investments, a position providing capital for ongoing clinical development.
The financial report follows a watershed moment for the company’s lead program, PM359, an ex vivo therapy for Chronic Granulomatous Disease (CGD).
The company announced the publication of PM359 Phase 1/2 clinical data in The New England Journal of Medicine, a milestone that supports its ongoing engagement with the FDA.
Based on the clinical progress to date, Prime Medicine disclosed its intent to submit a Biologics License Application (BLA) for the candidate.
While the CGD program provides clinical proof-of-concept for the platform, the company is now accelerating its in vivo liver franchise.
Prime Medicine confirmed it is on track for major regulatory milestones in 2026, with Investigational New Drug (IND) or Clinical Trial Application (CTA) filings planned for Wilson Disease in the first half of the year and Alpha-1 Antitrypsin Deficiency (AATD) by mid-2026.
Initial clinical data for both programs are anticipated in 2027.